Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease

Open Forum Infectious Diseases
Takanori AsakuraNaoki Hasegawa


Sitafloxacin (STFX) exhibits potent activity against Mycobacterium avium complex (MAC) in both in vitro and in vivo experiments. However, limited data are available for the clinical efficacy and adverse effects of STFX and the susceptibility of refractory MAC lung disease (MAC-LD) to the drug. Therefore, this study was aimed at evaluating the clinical efficacy and safety of an STFX-containing regimen for the treatment of refractory MAC-LD. We retrospectively evaluated treatment outcomes of 31 patients with refractory MAC-LD, who received an STFX-containing regimen for ≥4 weeks between January 2010 and July 2017. Refractory MAC-LD was defined as persistent positive sputum cultures for >6 months of macrolide-based standard therapy. Clarithromycin resistance (minimum inhibitory concentration [MIC] ≥32 μg/mL) was identified in 15 patients (48%). Twelve months after receiving the STFX-containing regimen, 26% and 19% of patients showed symptomatic and radiological responses, respectively. Although STFX-associated adverse effects were noted in 9 patients, their severity was grade 1 (National Cancer Institute Common Terminology Criteria); only 1 patient discontinued STFX because of suspected gastrointestinal disturbance. Negative sputu...Continue Reading


Sep 3, 1999·American Journal of Respiratory and Critical Care Medicine·E TanakaF Kuze
Jul 22, 2006·American Journal of Respiratory and Critical Care Medicine·David E GriffithRichard J Wallace
Sep 1, 2006·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshihiro KobashiMikio Oka
Feb 6, 2007·American Journal of Respiratory and Critical Care Medicine·David E GriffithUNKNOWN Infectious Disease Society of America
Feb 13, 2008·BMC Infectious Diseases·María T Milanés-VirellesUNKNOWN MACGAM Study Group
May 5, 2010·Nature Reviews. Microbiology·Michael A KohanskiJames J Collins
Sep 20, 2011·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Masaki FujitaYoichi Nakanishi
Mar 13, 2013·Antimicrobial Agents and Chemotherapy·Won-Jung KohSung Jae Shin
Feb 14, 2015·Clinics in Chest Medicine·D Rebecca Prevots, Theodore K Marras
May 19, 2016·Emerging Infectious Diseases·Ho NamkoongSatoshi Mitarai
Aug 12, 2016·Annals of the American Thoracic Society·Kozo MorimotoUNKNOWN Nontuberculous Mycobacteriosis Japan Research Consortium
Jun 6, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nakwon KwakJae-Joon Yim
Mar 24, 2018·The European Respiratory Journal·Jakko van IngenUNKNOWN for NTM-NET
May 5, 2018·BMC Infectious Diseases·Roland DielWouter Hoefsloot
Jul 18, 2018·Antimicrobial Agents and Chemotherapy·Byoung Soo KwonKyung-Wook Jo
Aug 3, 2018·Seminars in Respiratory and Critical Care Medicine·Jennifer AdjemianD Rebecca Prevots

❮ Previous
Next ❯


Jan 29, 2020·Expert Review of Anti-infective Therapy·Mohammad Javad NasiriMehdi Mirsaeidi
Nov 21, 2020·BMC Infectious Diseases·Kana KurokawaKazuhisa Takahashi
May 11, 2021·Frontiers in Medicine·Mohammad Javad NasiriMehdi Mirsaeidi
May 21, 2021·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Shi WuFupin Hu

❮ Previous
Next ❯

Methods Mentioned

surgical resection

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Related Papers

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
T FujikaneT Shimizu
© 2021 Meta ULC. All rights reserved